Cargando…

The Changes of Amygdala Transcriptome in Autism Rat Model After Arginine Vasopressin Treatment

BACKGROUND: Some studies have shown that arginine vasopressin (AVP) can significantly improve the social interaction disorder of autism, but the mechanism remains unclear. METHODS: Female Wistar rats were intraperitoneally injected with VPA or normal saline at embryonic day 12.5 to establish an auti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Bo, Zheng, Xiaoli, Chen, Yunhua, Yan, Xuehui, Peng, Jinggang, Liu, Yibu, Zhang, Yi, Tang, Lei, Wen, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990166/
https://www.ncbi.nlm.nih.gov/pubmed/35401102
http://dx.doi.org/10.3389/fnins.2022.838942
_version_ 1784683327882526720
author Zhou, Bo
Zheng, Xiaoli
Chen, Yunhua
Yan, Xuehui
Peng, Jinggang
Liu, Yibu
Zhang, Yi
Tang, Lei
Wen, Min
author_facet Zhou, Bo
Zheng, Xiaoli
Chen, Yunhua
Yan, Xuehui
Peng, Jinggang
Liu, Yibu
Zhang, Yi
Tang, Lei
Wen, Min
author_sort Zhou, Bo
collection PubMed
description BACKGROUND: Some studies have shown that arginine vasopressin (AVP) can significantly improve the social interaction disorder of autism, but the mechanism remains unclear. METHODS: Female Wistar rats were intraperitoneally injected with VPA or normal saline at embryonic day 12.5 to establish an autism model or normal control in their offspring. Male offspring prenatally exposed to VPA were randomly assigned to two groups: the VPA-induced autism model group and the AVP group. The rats in the AVP group were treated with intranasal AVP at postnatal day (PND) 21 and for 3 weeks. The VPA-induced autism model group was given the same dose of normal saline in the same way. Behavioral responses were evaluated in the open field and three-chambered social test apparatus; the expression levels of AVP in serum were detected by enzyme-linked immunosorbent assay kit, and the gene expression levels on the amygdala were measured by RNA-seq at PND42. RESULTS: Intranasal administration of AVP can significantly improve the social interaction disorder and elevate the levels of AVP in serum. Transcriptome sequencing results showed that 518 differently expressed genes (DEGs) were identified in the VPA-induced autism model group compared with the control in this study. Gene Ontology biological process enrichment analysis of DEGs showed that the VPA-induced autism model group had significant nervous system developmental impairments compared with the normal group, particularly in gliogenesis, glial cell differentiation, and oligodendrocyte differentiation. Gene Set Enrichment Analysis (GSEA) enrichment analysis also showed that biological process of oligodendrocyte differentiation, axoneme assembly, and axon ensheathment were inhibited in the VPA-induced autism model group. Pathway enrichment analysis of DEGs between the control and VPA-induced autism model group showed that the PI3K/AKT and Wnt pathways were significantly dysregulated in the VPA-induced autism model group. Few DEGs were found when compared with the transcriptome between the VPA-induced autism model group and the AVP treatment group. GSEA enrichment analysis showed deficits in oligodendrocyte development and function were significantly improved after AVP treatment; the pathways were mainly enriched in the NOTCH, mitogen-activated protein kinase, and focal adhesion signaling pathways, but not in the PI3K/AKT and Wnt pathways. The expression patterns analysis also showed the same results. CONCLUSION: AVP can significantly improve the social interaction disorder of VPA-induced autism model, and AVP may target behavioral symptoms in autism by modulating the vasopressin pathways, rather than primary disease mechanisms.
format Online
Article
Text
id pubmed-8990166
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89901662022-04-09 The Changes of Amygdala Transcriptome in Autism Rat Model After Arginine Vasopressin Treatment Zhou, Bo Zheng, Xiaoli Chen, Yunhua Yan, Xuehui Peng, Jinggang Liu, Yibu Zhang, Yi Tang, Lei Wen, Min Front Neurosci Neuroscience BACKGROUND: Some studies have shown that arginine vasopressin (AVP) can significantly improve the social interaction disorder of autism, but the mechanism remains unclear. METHODS: Female Wistar rats were intraperitoneally injected with VPA or normal saline at embryonic day 12.5 to establish an autism model or normal control in their offspring. Male offspring prenatally exposed to VPA were randomly assigned to two groups: the VPA-induced autism model group and the AVP group. The rats in the AVP group were treated with intranasal AVP at postnatal day (PND) 21 and for 3 weeks. The VPA-induced autism model group was given the same dose of normal saline in the same way. Behavioral responses were evaluated in the open field and three-chambered social test apparatus; the expression levels of AVP in serum were detected by enzyme-linked immunosorbent assay kit, and the gene expression levels on the amygdala were measured by RNA-seq at PND42. RESULTS: Intranasal administration of AVP can significantly improve the social interaction disorder and elevate the levels of AVP in serum. Transcriptome sequencing results showed that 518 differently expressed genes (DEGs) were identified in the VPA-induced autism model group compared with the control in this study. Gene Ontology biological process enrichment analysis of DEGs showed that the VPA-induced autism model group had significant nervous system developmental impairments compared with the normal group, particularly in gliogenesis, glial cell differentiation, and oligodendrocyte differentiation. Gene Set Enrichment Analysis (GSEA) enrichment analysis also showed that biological process of oligodendrocyte differentiation, axoneme assembly, and axon ensheathment were inhibited in the VPA-induced autism model group. Pathway enrichment analysis of DEGs between the control and VPA-induced autism model group showed that the PI3K/AKT and Wnt pathways were significantly dysregulated in the VPA-induced autism model group. Few DEGs were found when compared with the transcriptome between the VPA-induced autism model group and the AVP treatment group. GSEA enrichment analysis showed deficits in oligodendrocyte development and function were significantly improved after AVP treatment; the pathways were mainly enriched in the NOTCH, mitogen-activated protein kinase, and focal adhesion signaling pathways, but not in the PI3K/AKT and Wnt pathways. The expression patterns analysis also showed the same results. CONCLUSION: AVP can significantly improve the social interaction disorder of VPA-induced autism model, and AVP may target behavioral symptoms in autism by modulating the vasopressin pathways, rather than primary disease mechanisms. Frontiers Media S.A. 2022-03-25 /pmc/articles/PMC8990166/ /pubmed/35401102 http://dx.doi.org/10.3389/fnins.2022.838942 Text en Copyright © 2022 Zhou, Zheng, Chen, Yan, Peng, Liu, Zhang, Tang and Wen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Zhou, Bo
Zheng, Xiaoli
Chen, Yunhua
Yan, Xuehui
Peng, Jinggang
Liu, Yibu
Zhang, Yi
Tang, Lei
Wen, Min
The Changes of Amygdala Transcriptome in Autism Rat Model After Arginine Vasopressin Treatment
title The Changes of Amygdala Transcriptome in Autism Rat Model After Arginine Vasopressin Treatment
title_full The Changes of Amygdala Transcriptome in Autism Rat Model After Arginine Vasopressin Treatment
title_fullStr The Changes of Amygdala Transcriptome in Autism Rat Model After Arginine Vasopressin Treatment
title_full_unstemmed The Changes of Amygdala Transcriptome in Autism Rat Model After Arginine Vasopressin Treatment
title_short The Changes of Amygdala Transcriptome in Autism Rat Model After Arginine Vasopressin Treatment
title_sort changes of amygdala transcriptome in autism rat model after arginine vasopressin treatment
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990166/
https://www.ncbi.nlm.nih.gov/pubmed/35401102
http://dx.doi.org/10.3389/fnins.2022.838942
work_keys_str_mv AT zhoubo thechangesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT zhengxiaoli thechangesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT chenyunhua thechangesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT yanxuehui thechangesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT pengjinggang thechangesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT liuyibu thechangesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT zhangyi thechangesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT tanglei thechangesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT wenmin thechangesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT zhoubo changesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT zhengxiaoli changesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT chenyunhua changesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT yanxuehui changesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT pengjinggang changesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT liuyibu changesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT zhangyi changesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT tanglei changesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment
AT wenmin changesofamygdalatranscriptomeinautismratmodelafterargininevasopressintreatment